Potential of non-antiarrhythmic drugs to provide an innovative upstream approach to the pharmacological prevention of sudden cardiac death

Bibliography

• MYERBURG RJ, KESSLER KM, CASTELLANOS A: Sudden cardiac death. Structure, function, and time-dependence of risk. Circulation (1992) 85(Suppl. 1):I2-10.
   PubMed Web of Science ®Google Scholar
• MYERBURG RJ, INTERIAN A Jr, MITRANI RM, KESSLER KM, CASTELLANOS A: Frequency of sudden cardiac death and profiles of risk. Am. J. Cardiol. (1997) 80(5B):10F-19F.
   Web of Science ®Google Scholar
• JOSEPHSON M, WELLENS HJ: Implantable defibrillators and sudden cardiac death. Circulation (2004) 109(22):2685-2691.
   PubMed Web of Science ®Google Scholar
• ZHENG ZJ, CROFT JB, GILES WH, MENSAH GA: Sudden cardiac death in the United States, 1989 to 1998. Circulation (2001) 104(18):2158-2163.
   PubMed Web of Science ®Google Scholar
• ZIPES DP, CAMM AJ, BORGGREFE M et al.: ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J. Am. Coll. Cardiol. (2006) 48(5):e247-e346.
   Web of Science ®Google Scholar
• BORIANI G, BIFFI M, MARTIGNANI C et al.: Cardioverter-defibrillators after MADIT-II: the balance between weight of evidence and treatment costs. Eur. J. Heart Fail. (2003) 5(4):419-425.
   Web of Science ®Google Scholar
• BORIANI G, BIFFI M, MARTIGNANI C, BARTOLINI P, BRANZI A: Implantable cardioverter defibrillators for ventricular tachyarrhythmia: current status and technological evolution. Int. J. Artif. Organs (2001) 24(7):419-424.
   Web of Science ®Google Scholar
• BORIANI G, BIFFI M, MARTIGNANI C, GALLINA M, BRANZI A: Cost-effectiveness of implantable cardioverter-defibrillators. Eur. Heart J. (2001) 22(12):990-996.
   Web of Science ®Google Scholar
• THE CARDIAC ARRHYTHMIASUPPRESSION TRIAL (CAST) INVESTIGATORS: Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N. Engl. J. Med. (1989) 321(6):406-412.
   PubMed Web of Science ®Google Scholar
• BARDY GH, LEE KL, MARK DB et al.: Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. (2005) 352(3):225-237.
   PubMed Web of Science ®Google Scholar
• LOPEZ-SENDON J, SWEDBERG K, MCMURRAY J et al.: Expert consensus document on β-adrenergic receptor blockers. Eur. Heart J. (2004) 25(15):1341-1362.
   Web of Science ®Google Scholar
• CIBIS INVESTIGATORS AND COMMITTEES: A randomized trial of β-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation (1994) 90(4):1765-1773.
   PubMed Web of Science ®Google Scholar
• CIBIS II INVESTIGATORS AND COMMITTEES: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (1999) 353(9146):9-13.
   PubMed Web of Science ®Google Scholar
• MERIT-HF STUDY GROUP: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (1999) 353(9169):2001-2007.
   PubMed Web of Science ®Google Scholar
• PACKER M, COATS AJ, FOWLER MB et al.: Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. (2001) 344(22):1651-1658.
   PubMed Web of Science ®Google Scholar
• THE β-BLOCKER EVALUATION OFSURVIVAL TRIAL INVESTIGATORS: A trial of the β-blocker bucindolol in patients with advanced chronic heart failure. N. Engl. J. Med. (2001) 344:1659-1667.
   PubMed Web of Science ®Google Scholar
• DARGIE HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (2001) 357(9266):1385-1390.
   PubMed Web of Science ®Google Scholar
• POOLE-WILSON PA, SWEDBERG K, CLELAND JG et al.: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet (2003) 362(9377):7-13.
   PubMed Web of Science ®Google Scholar
• LECHAT P, PACKER M, CHALON S et al.: Clinical effects of β-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation (1998) 98(12):1184-1191.
   PubMed Web of Science ®Google Scholar
• BROPHY JM, JOSEPH L, ROULEAU JL: β-Blockers in congestive heart failure. A Bayesian meta-analysis. Ann. Intern. Med. (2001) 134(7):550-560.
   PubMed Web of Science ®Google Scholar
• LEE S, SPENCER A: β-Blockers to reduce mortality in patients with systolic dysfunction: a meta-analysis. J. Fam. Pract. (2001) 50(6):499-504.
   Google Scholar
• CLEOPHAS TJ, ZWINDERMAN AH: β-blockers and heart failure: meta-analysis of mortality trials. Int. J. Clin. Pharmacol. Ther. (2001) 39(9):383-388.
   Web of Science ®Google Scholar
• FREEMANTLE N, CLELAND J, YOUNG P, MASON J, HARRISON J: β blockade after myocardial infarction: systematic review and meta regression analysis. Br. Med. J. (1999) 318(7200):1730-1737.
   PubMed Web of Science ®Google Scholar
• DULIN BR, HAAS SJ, ABRAHAM WT, KRUM H: Do elderly systolic heart failure patients benefit from β blockers to the same extent as the non-elderly? Meta-analysis of > 12,000 patients in large-scale clinical trials. Am. J. Cardiol. (2005) 95(7):896-898.
   Web of Science ®Google Scholar
• PRIORI SG, ALIOT E, BLOMSTROM-LUNDQVIST C et al.: Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur. Heart J. (2001) 22(16):1374-1450.
   Web of Science ®Google Scholar
• ALBERTE C, ZIPES DP: Use of nonantiarrhythmic drugs for prevention of sudden cardiac death. J. Cardiovasc. Electrophysiol. (2003) 14(Suppl. 9):S87-S95.
   Google Scholar
• STIER CT, CHANDER PN, ROCHA R: Aldosterone as a mediator in cardiovascular injury. Cardiol. Rev. (2002) 10(2):97-107.
   Google Scholar
• BARR CS, LANG CC, HANSON J et al.: Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am. J. Cardiol. (1995) 76(17):1259-1265.
   Web of Science ®Google Scholar
• MACFADYEN RJ, BARR CS, STRUTHERS AD: Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc. Res. (1997) 35(1):30-34.
   PubMed Web of Science ®Google Scholar
• FARQUHARSON CA, STRUTHERS AD: Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin. Sci. (Lond.) (2002) 103(4):425-431.
   Google Scholar
• PITT B, ZANNAD F, REMME WJ et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. (1999) 341(10):709-717.
   PubMed Web of Science ®Google Scholar
• PITT B, REMME W, ZANNAD F et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. (2003) 348(14):1309-1321.
   PubMed Web of Science ®Google Scholar
• THE CONSENSUS TRIALSTUDY GROUP: Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. (1987) 316(23):1429-1435.
   PubMed Web of Science ®Google Scholar
• THE SOLVD INVESTIGATORS: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. (1991) 325(5):293-302.
   PubMed Web of Science ®Google Scholar
• THE SOLVD INVESTIGATORS: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. (1992) 327(10):685-691.
   PubMed Web of Science ®Google Scholar
• COHN JN, JOHNSON G, ZIESCHE S et al.: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. (1991) 325(5):303-310.
   PubMed Web of Science ®Google Scholar
• PFEFFER MA, BRAUNWALD E, MOYE LA et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. (1992) 327(10):669-677.
   PubMed Web of Science ®Google Scholar
• THE ACUTE INFARCTION RAMIPRIL EFFICACY (AIRE) STUDY INVESTIGATORS: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet (1993) 342(8875):821-828.
   PubMed Web of Science ®Google Scholar
• THE GISSI-3 INVESTIGATORS: GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. Lancet (1994) 343(8906):1115-1122.
   PubMed Web of Science ®Google Scholar
• AMBROSIONI E, BORGHI C, MAGNANI B: The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N. Engl. J. Med. (1995) 332(2):80-85.
   PubMed Web of Science ®Google Scholar
• KOBER L, TORP-PEDERSEN C, CARLSEN JE et al.: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N. Engl. J. Med. (1995) 333(25):1670-1676.
   PubMed Web of Science ®Google Scholar
• THE ISIS-4 INVESTIGATORS: ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet (1995) 345(8951):669-685.
   PubMed Web of Science ®Google Scholar
• YUSUF S, SLEIGHT P, POGUE J et al.: Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. (2000) 342(3):145-153.
   PubMed Web of Science ®Google Scholar
• FOX KM: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet (2003) 362(9386):782-788.
   PubMed Web of Science ®Google Scholar
• BRAUNWALD E, DOMANSKI MJ, FOWLER SE et al.: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med. (2004) 351(20):2058-2068.
   PubMed Web of Science ®Google Scholar
• DOMANSKI MJ, EXNER DV, BORKOWF CB et al.: Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J. Am. Coll. Cardiol. (1999) 33(3):598-604.
   Web of Science ®Google Scholar
• FLATHER MD, YUSUF S, KOBER L et al.: Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet (2000) 355(9215):1575-1581.
   PubMed Web of Science ®Google Scholar
• TEO KK, MITCHELL LB, POGUE J et al.: Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction. Circulation (2004) 110(11):1413-1417.
   PubMed Web of Science ®Google Scholar
• DAGENAIS GR, POGUE J, FOX K, SIMOONS ML, YUSUF S: Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet (2006) 368(9535):581-588.
   PubMed Web of Science ®Google Scholar
• AL-MALLAH MH, TLEYJEH IM, ABDEL-LATIF AA, WEAVER WD: Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol. (2006) 47(8):1576-1583.
   Web of Science ®Google Scholar
• DANCHIN N, CUCHERAT M, THUILLEZ C et al.: Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials. Arch. Intern. Med. (2006) 166(7):787-796.
   PubMed Web of Science ®Google Scholar
• PITT B, SEGAL R, MARTINEZ FA et al.: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet (1997) 349(9054):747-752.
   PubMed Web of Science ®Google Scholar
• PITT B, POOLE-WILSON PA, SEGAL R et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 355(9215):1582-1587.
   PubMed Web of Science ®Google Scholar
• COHN JN, TOGNONI G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. (2001) 345(23):1667-1675.
   PubMed Web of Science ®Google Scholar
• DICKSTEIN K, KJEKSHUS J: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet (2002) 360(9335):752-760.
   PubMed Web of Science ®Google Scholar
• DAHLOF B, DEVEREUX RB, KJELDSEN SE et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359(9311):995-1003.
   PubMed Web of Science ®Google Scholar
• YOUNG JB, DUNLAP ME, PFEFFER MA et al.: Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation (2004) 110(17):2618-2626.
   PubMed Web of Science ®Google Scholar
• PFEFFER MA, MCMURRAY JJ, VELAZQUEZ EJ et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. (2003) 349(20):1893-1906.
   PubMed Web of Science ®Google Scholar
• JONG P, DEMERS C, MCKELVIE RS, LIU PP: Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol. (2002) 39(3):463-470.
   Web of Science ®Google Scholar
• LEE VC, RHEW DC, DYLAN M et al.: Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann. Intern. Med. (2004) 141(9):693-704.
   PubMed Web of Science ®Google Scholar
• SCANDINAVIAN SIMVASTATIN SURVIVAL STUDYGROUP: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344(8934):1383-1389.
   PubMed Web of Science ®Google Scholar
• SHEPHERD J, COBBE SM, FORD I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. (1995) 333(20):1301-1307.
   PubMed Web of Science ®Google Scholar
• SACKS FM, PFEFFER MA, MOYE LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N. Engl. J. Med. (1996) 335(14):1001-1009.
   PubMed Web of Science ®Google Scholar
• THE LIPID STUDY GROUP: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med. (1998) 339(19):1349-1357.
   PubMed Web of Science ®Google Scholar
• DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA (1998) 279(20):1615-1622.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ GG, OLSSON AG, EZEKOWITZ MD et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA (2001) 285(13):1711-1718.
   PubMed Web of Science ®Google Scholar
• HEART PROTECTION STUDYCOLLABORATIVE GROUP: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360(9326):7-22.
   PubMed Web of Science ®Google Scholar
• SHEPHERD J, BLAUW GJ, MURPHY MB et al.: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 360(9346):1623-1630.
   PubMed Web of Science ®Google Scholar
• ALLHAT COLLABORATIVE RESEARCH GROUP: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA (2002) 288(23):2998-3007.
   PubMed Web of Science ®Google Scholar
• SEVER PS, DAHLOF B, POULTER NR et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet (2003) 361(9364):1149-1158.
   PubMed Web of Science ®Google Scholar
• THOMPSON PL, MEREDITH I, AMERENA J et al.: Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial. Am. Heart J. (2004) 148(1):e2.
   PubMed Web of Science ®Google Scholar
• CANNON CP, BRAUNWALD E, MCCABE CH et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. (2004) 350(15):1495-1504.
   PubMed Web of Science ®Google Scholar
• LAROSA JC, GRUNDY SM, WATERS DD et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. (2005) 352(14):1425-1435.
   PubMed Web of Science ®Google Scholar
• LAROSA JC, HE J, VUPPUTURI S: Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA (1999) 282(24):2340-2346.
   PubMed Web of Science ®Google Scholar
• GRUNDY SM, CLEEMAN JI, MERZ CN et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J. Am. Coll. Cardiol. (2004) 44(3):720-732.
   Web of Science ®Google Scholar
• VRECER M, TURK S, DRINOVEC J, MRHAR A: Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials. Int. J. Clin. Pharmacol. Ther. (2003) 41(12):567-577.
   Web of Science ®Google Scholar
• CHEUNG BM, LAUDER IJ, LAU CP, KUMANA CR: Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br. J. Clin. Pharmacol. (2004) 57(5):640-651.
   Web of Science ®Google Scholar
• PRIORI SG, ALIOT E, BLOMSTROM-LUNDQVIST C et al.: Update of the guidelines on sudden cardiac death of the European Society of Cardiology. Eur. Heart J. (2003) 24(1):13-15.
   Web of Science ®Google Scholar
• REIFFEL JA, MCDONALD A: Antiarrhythmic effects of omega-3 fatty acids. Am. J. Cardiol. (2006) 98( 4Suppl. 1):50.
   Google Scholar
• BURR ML, FEHILY AM, GILBERT JF et al.: Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet (1989) 2(8666):757-761.
   PubMed Web of Science ®Google Scholar
• SINGH RB, NIAZ MA, SHARMA JP et al.: Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival-4. Cardiovasc. Drugs Ther. (1997) 11(3):485-491.
   Google Scholar
• DE LORGERIL M, SALEN P, MARTIN JL et al.: Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation (1999) 99(6):779-785.
   PubMed Web of Science ®Google Scholar
• GISSI-PREVENZIONE INVESTIGATORS: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. Lancet (1999) 354(9177):447-455.
   PubMed Web of Science ®Google Scholar
• ALBERT CM, HENNEKENS CH, O’DONNELL CJ et al.: Fish consumption and risk of sudden cardiac death. JAMA (1998) 279(1):23-28.
   PubMed Web of Science ®Google Scholar
• SISCOVICK DS, RAGHUNATHAN TE, KING I et al.: Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA (1995) 274(17):1363-1367.
   PubMed Web of Science ®Google Scholar
• JOHANSEN O, BREKKE M, SELJEFLOT I, ABDELNOOR M, ARNESEN H: N-3 fatty acids do not prevent restenosis after coronary angioplasty: results from the CART study. Coronary Angioplasty Restenosis Trial. J. Am. Coll. Cardiol. (1999) 33(6):1619-1626.
   Web of Science ®Google Scholar
• BUCHER HC, HENGSTLER P, SCHINDLER C, MEIER G: N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am. J. Med. (2002) 112(4):298-304.
   PubMed Web of Science ®Google Scholar
• YZEBE D, LIEVRE M: Fish oils in the care of coronary heart disease patients: a meta-analysis of randomized controlled trials. Fundam. Clin. Pharmacol. (2004) 18(5):581-592.
   Google Scholar
• WANG C, HARRIS WS, CHUNG M et al.: n-3 Fatty acids from fish or fish-oil supplements, but not α-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am. J. Clin. Nutr. (2006) 84(1):5-17.
   Web of Science ®Google Scholar
• BROUWER IA, ZOCK PL, CAMM AJ et al.: Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA (2006) 295(22):2613-2619.
   PubMed Web of Science ®Google Scholar
• STUDER M, BRIEL M, LEIMENSTOLL B, GLASS TR, BUCHER HC: Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch. Intern. Med. (2005) 165(7):725-730.
   PubMed Web of Science ®Google Scholar